Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-16 07:08 am Sale |
2020-12-31 | 13G | Vir Biotechnology, Inc. VIR |
Alaska Permanent Fund Corp | 3,893,040 3.060% |
-1,662,516 (-29.93%) |
Filing History |
| 2021-02-12 5:00 pm Purchase |
2020-12-31 | 13G | Vir Biotechnology, Inc. VIR |
SCANGOS GEORGE A | 7,001,308 5.500% |
52,329 (+0.75%) |
Filing History |
| 2021-02-11 06:02 am Purchase |
2020-12-31 | 13G | Vir Biotechnology, Inc. VIR |
Temasek Holdings (Private) Ltd | 5,499,999 4.300% |
5,499,999 (New Position) |
Filing History |
| 2020-07-29 3:50 pm Unchanged |
2020-07-08 | 13D | Vir Biotechnology, Inc. VIR |
ARCH Venture Fund IX, L.P. | 28,666,663 23.000% |
0 (Unchanged) |
Filing History |
| 2020-05-07 07:04 am Unchanged |
2020-04-14 | 13G | Vir Biotechnology, Inc. VIR |
Alaska Permanent Fund Corp | 5,555,556 5.060% |
0 (Unchanged) |
Filing History |
| 2020-05-04 4:18 pm Purchase |
2020-04-22 | 13G | Vir Biotechnology, Inc. VIR |
GSK PLC | 6,626,027 6.030% |
6,626,027 (New Position) |
Filing History |